Glaucoma Drug's Flop Has OCUL Stock Spiraling

Several analysts, including Cowen and Raymond James hit the stock with downgrades

Digital Content Manager
May 21, 2019 at 9:37 AM
facebook X logo linkedin


Pharma stock Ocular Therapeutix Inc (NASDAQ:OCUL) is in hot water today, down 11% at $3.00 in early trading, and pacing for its worst day since Dec. 3. The stock is fresh off a new record low of $2.78, too, after the company's glaucoma treatment, OTX-TP, fell short of its main goal in a late-stage study.

A round of bear notes is doing the equity no favors. Cowen and Company downgraded OCUL to a "market perform" from "outperform," and slashed its target price by a whopping $10 dollars to $3 a share, while Raymond James cut its rating to "outperform" from "strong buy," and dropped its target price to $5 from $11. Wainwright joined suit, cutting its price target to $9 from $12.

Considering the stock's longer-term technical troubles, this analyst drubbing feels long overdue. OCUL stock has been trading in a channel of lower highs and lows since a late-February spike, pressured by its declining 100-day moving average. Plus, Ocular Therapeutics has lost 56% year-over-year. Nevertheless, four "strong buy" ratings were on the table at last night's close, while the consensus 12-month target price of $10.17 more than doubles the security's current price.

Shorts are likely celebrating the equity's bear gap today, as short interest shot up over 14% in the last two reporting periods. The 8.4 million shares sold short represents a whopping 28.9% of the stocks available float, or nearly three weeks of trading at OCUL's average pace. However, these traders are sidelined today, with the stock landing on the short-sale restricted list.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI